Advertisement

Pharmaceutisch Weekblad

, Volume 5, Issue 2, pp 57–60 | Cite as

Formulation of a stable vidarabine infusion fluid

  • L. M. L. Stolk
  • W. Huisman
  • H. D. Nordemann
  • A. Vyth
Original Articles

Abstract

Decomposition of vidarabine in a 5% glucose infusion fluid after steam sterilization was measured byhplc andtlc analysis. After sterilization for 60 minutes at 100°C and 20 minutes at 120°C no degradation could be observed. A slight but significant degradation was observed after sterilization for 60 minutes at 120°C followed by storage for eight months. Assuming 5% loss of content to be acceptable, it was concluded that a vidarabine infusion fluid can be sterilized for 20 minutes at 120°C and stored at room temperature for at least eight months afterwards.

Keywords

Public Health Glucose Internal Medicine Infusion Fluid Glucose Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pollard RB, Smith JL, Neal EA, Gregory PB, Merigan TC, Robinson WS. Effect of vidarabine on chronic hepatitis B virus infection. JAMA 1978;239:1648–50.Google Scholar
  2. 2.
    Gilman AG, Goodman LS, Gilman A. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th ed. New York: Macmillan Company, 1980:1242–3.Google Scholar
  3. 3.
    Pavan-Langston D, Buchanan RA, Alford CA, eds. Adenine Arabinoside: An antiviral Agent. New York: Raven Press, 1975.Google Scholar
  4. 4.
    Anonymus. Vira-A® for infusion. Basic medical literature INI-504-L-78. Warner Lambert Co, 1978.Google Scholar
  5. 5.
    LePage GA, Naik SR, Katakkar SB, Khalig A. 9-beta-D-arabinofuranosyladenine 5′-phosphate metabolism and excretion in humans. Cancer Res 1975: 35;3036–40.Google Scholar
  6. 6.
    Preiksaitis JK, Lank B, Ng PK, Brox L, LePage GA, Tyrell DL. Effect of Liver Disease on Pharmacokinetics and toxicity of 9-β-D-Arabinofuranosyladenine-5′- Phosphate. J Infect Dis 1981;144:358–64.Google Scholar
  7. 7.
    Whitley RJ, Tucker BC, Kinkel AW, et al. Pharmacology, Tolerance and Antiviral Activity of Vidarabine Monophosphate in Humans. Antimicrob Agents Chemother 1980;18:709–15.Google Scholar
  8. 8.
    Hong WH, Szulczewski DH. Stability-Indicating Assay for Vidarabine. J Pharm Sci 1979;68:499–503.Google Scholar
  9. 9.
    Pechtold F, Rentsch H. Der Nachweis und die quantitative Bestimmung von Adenosin in pharmazeutischen Zubereitungen durch Dünnschichtchromatographie. Arzneimittelforsch 1967;17:57–9.Google Scholar
  10. 10.
    Hartwick RA, Brown PR, Selective Analysis for Adenosine Using Reversed-Phase High-Pressure Liquid Chromatography. J Chromatogr 1977;143:383–9.Google Scholar
  11. 11.
    Weast RC, Selby SM, eds. Handbook of Chemistry and Physics, 47th ed. Cleveland, Ohio, USA: Chemical Rubber Co. 1966:A-244.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1983

Authors and Affiliations

  • L. M. L. Stolk
    • 1
  • W. Huisman
    • 1
  • H. D. Nordemann
    • 2
  • A. Vyth
    • 1
  1. 1.Pharmacy of the University Hospital of AmsterdamAZ AmsterdamThe Netherlands
  2. 2.Faculty of FarmacyUniversity of AmsterdamTV AmsterdamThe Netherlands

Personalised recommendations